je.st
news
The top biopharmaceutical deals of 2014
2014-12-15 16:30:41| Biotech - Topix.net
In January, Teva made an unsolicited offer to buy NuPathe Inc. of Malvern, Pa., for $114 million - topping a $105 million offer Endo International put in play at the end of 2013. Teva ultimately bought NuPathe, the developer of the migraine headache treatment Zecuity, for $144 billion in February.
Tags: top
deals
deals top
biopharmaceutical
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||